Key result
Losartan dose-dependently reduces platelet activation, an effect absent with candesartan and limited with valsartan.
Why the study?
Do different AT1-receptor antagonists inhibit TxA2-dependent human platelet activation?
Population
Human platelets obtained from healthy volunteers, stimulated with thromboxane A2 analogue U46619 (10 mol/L)
Design
Preclinical
Authors
Loading...
Losartan may uniquely inhibit TxA2 platelet activation among ARBs; leaves open human clinical relevance.
Do different AT1-receptor antagonists inhibit TxA2-dependent human platelet activation?
Losartan exhibits a specific ability to inhibit TxA2-dependent platelet activation that is not shared by all AT1-receptor antagonists.
Núñez et al. (2000) studied Healthy volunteers. Losartan vs. Valsartan and candesartan was evaluated on Inhibition of TxA2-dependent human platelet activation. Losartan dose-dependently reduced U46619-stimulated platelet activation, an effect seen only at maximal doses with valsartan and not at all with candesartan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: